AVE(SH:688067)2022-04-27 16:00Financial Performance - The company's operating revenue for 2021 was CNY 210,668,650.51, representing a year-on-year increase of 16.91% compared to CNY 180,199,388.49 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 31,275,040.94, a 3.90% increase from CNY 30,100,264.86 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 23,985,348.09, which is a decrease of 9.14% from CNY 26,399,541.32 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 47,185,681.68, showing a slight increase of 0.54% from CNY 46,932,841.29 in 2020[21]. - The total assets at the end of 2021 were CNY 547,610,359.66, an increase of 84.65% compared to CNY 296,570,337.16 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 477,579,653.02, reflecting a significant growth of 101.75% from CNY 236,719,197.28 at the end of 2020[21]. - The basic earnings per share for 2021 were CNY 0.53, a decrease of 10.17% from CNY 0.59 in 2020[22]. - The company's operating costs rose to RMB 86,611,317.38, reflecting an 18.19% increase from RMB 73,284,277.39 in the previous year[84]. - The gross profit margin for the main business was 58.81%, a decrease of 0.19 percentage points compared to the previous year[86]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 14.81% in 2021, up from 12.55% in 2020, indicating a focus on innovation[22]. - The company invested CNY 31.20 million in R&D, representing a year-on-year increase of 37.94%[31]. - The company has accumulated a vast clinical specimen image database over nearly 20 years, enhancing automatic recognition capabilities for various specimens[51]. - The company is focusing on the automation of medical testing, accumulating a series of core technologies through original innovation and technology integration[51]. - The company has developed key technologies in intelligent medical testing, particularly in automatic microscopy, filling a gap in the market for automated morphological testing[164]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[21]. - The company signed 7 new international agents in 2021, laying the groundwork for market expansion in the U.S.[30]. - The company aims to expand its product portfolio to meet the increasing demand for home healthcare, particularly in cancer screening and chronic disease monitoring[111]. - The marketing strategy includes expanding domestic and international channels, with a focus on increasing market share and brand recognition[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[129]. Corporate Governance - The company has established a scientific and standardized corporate governance structure in compliance with relevant laws and regulations[119]. - The company has not reported any significant changes in competition with its controlling shareholders or related parties[119]. - The company has not implemented any differential voting rights arrangements during the reporting period[124]. - The governance structure complies with the regulations set forth by the China Securities Regulatory Commission[119]. - The company has a clear process for the appointment and remuneration of its directors and supervisors, ensuring transparency and accountability[135]. Risks and Challenges - The company has not achieved profitability since its listing[4]. - The company faces risks related to product price declines due to rapid technological advancements and government pricing regulations in clinical testing[78]. - The ongoing COVID-19 pandemic has led to a decrease in hospital visits, negatively affecting the demand for the company's reagent consumables[81]. - The company has a risk of losing key technical personnel, which could adversely affect its R&D capabilities[78]. - The competitive landscape in the in vitro diagnostics market has intensified, with both domestic and international companies increasing their market share[80]. Social Responsibility and Environmental Initiatives - The company actively engages in social responsibility initiatives, focusing on health technology and improving human health standards[164]. - The company has implemented measures to reduce carbon emissions and improve energy efficiency, including the use of high-efficiency energy-saving equipment[159][160]. - The company has a comprehensive waste management system, ensuring proper recycling and disposal of solid waste[162]. - In December 2021, the company donated 80,000 yuan to the Hunan Women's and Children's Development Foundation[168]. - The company contributed 24,600 yuan to public welfare projects in December 2021, assisting vocational school students in difficult family situations[168]. Shareholder Information - The proposed cash dividend distribution is RMB 3.00 per 10 shares, totaling RMB 20,400,000.00, which accounts for 65.23% of the net profit attributable to shareholders for 2021[5]. - The total share capital as of December 31, 2021, is 68,000,000 shares[5]. - The company has not reported any significant reliance on a single customer or supplier, indicating a diversified customer and supplier base[97][98]. - The company has a total of 18 employees holding shares, representing 3.54% of the total workforce[171]. - Employee shareholding amounts to 3,651,000 shares, accounting for 53.69% of the total share capital[171].